LCLdO has received lecture fees from Aché, Danone, Nestlé, Sanofi, Takeda and Thermofisher and consultancy fees from Novartis. RT has received fees for lectures, congresses as well as study support from/conducted clinical trials for AbbVie, ALK-Abello, CSL-Behring, Lilly, Novartis, Pfizer, Sanofi-Genzyme, Takeda. MFR reports grants from lnstituto de Salud Carlos III, Spanish Goverment, grants and personal fees from Aimmune Therapeutics, personal fees from Diater, personal fees from Ediciones Mayo, personal fees from GA2LEN, personal fees from HAL Allergy, personal fees from EPG Health, personal fees from MEDSCAPE, personal fees from NOVARTIS, personal fees from DBV, personal fees from Reacta Healthcare, from SPRIM, outside the submitted work. KN reports personal fees from Nutricia/Danone (lecture fees), personal fees from AimmuneTherapeutics (consulting fees), outside the submitted work. CP received honoraria (speaker honoraria or honoraria as a consultant) and travel support from: Novartis, BMS, MSD, Merck Serono, MSD, Celgene, AbbVie, Sunpharma, Pierre Fabre, UCB, Nutricia Milupa and LEO. FR has received outside the submitted work personal fees for lectures and/or advisory boards from ALK-Abelló Arzneimittel GmbH, Firma Allergopharma GmbH & Co. KG, Blueprint medicines (Germany) GmbH, Boehringer Ingelheim, Mylan Germany Team, Novartis, ThermoFisher Diagnostics Austria GmbH and UCB Pharma GmbH. DSL has received outside the submitted work personal fees for lectures and/or advisory boards from Nutricia, ALK, Stallergènes, Thermofischer, Novartis and Aimmune. KH has received research funding from Thermo Fisher and consultancy or lecture fees from Allergopharma, ALK-Abello, Blueprint, Deciphera, Leo Pharma, Menarini, Novartis, Pfizer, Takeda and Thermo Fisher. AK received travel reimbursement from Allergopharma, personal fees (advisory board) and speaker honoraria from Menarini outside the submitted work. NGP has received speaker/advisor fees from Abbott, Abbvie, ALK, Asit Biotech, AstraZeneca, Biomay, Boehringer Ingelheim, GSK, HAL, Faes Farma, Medscape, Menarini, MSD, Novartis, Nutricia, OM Pharma, Regeneron, Sanofi, Takeda, Viatris. NW is or recently was a speaker and/or advisor for and/or has received research funding or is/was involved in clinical trials of/from ALK-Abelló, Novartis Pharma GmbH, Allergopharma GmbH &Co KG, Sanofi-Aventis Deutschland GmbH, Takeda, Blueprint, Abbvie GmbH & Co KG. MW declares the receipt of honoraria or consultation fees by the following companies:Novartis Pharma GmbH, , Sanofi-Aventis Deutschland GmbH, , DBV Technologies S.A, Aimmune Therapeutics UK Limited, Regeneron Pharmaceuticals, Inc, Leo Pharma GmbH, Boehringer Ingelheim Pharma GmbH &Co.KG, , AstraZenceca GmbH, Worg Pharmaceutics (Hangzhou) Co. Ltd, ALK-Abelló Arzneimittel GmbH, , Lilly Deutschland GmbH, Kymab Limited, Phadia GmbH, Amgen GmbH and Viatris , outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.